EpilepsyNCT07883980
Antiseizure Medications and CBC in Children With Epilepsy
An observational study of Epilepsy, run by Assiut University.
Trial summary
This prospective study aims to assess changes in complete blood count parameters among Egyptian children with epilepsy receiving antiseizure medications. Read more about this study
- Who is it for?
- Ages 1 year to 18 years
- Conditions the study is for
- Epilepsy
- How many people
- 80 participants
- Where
- No sites listed yet
- Study dates
- 20 Oct 2026to 1 Mar 2028
- Phase
- Observational
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 1 year to 18 years
- All sexes
- No healthy volunteers
- Child, Adult
Study population: Egyptian children aged 1 to 18 years newly diagnosed with epilepsy who have not previously received antiseizure medications, followed at Assiut University Children's Hospital.
Who may be able to join
- Children aged 1 to 18 years
- Diagnosed with epilepsy
- Newly diagnosed and not previously received antiseizure medications
- Written informed consent from parent or legal guardian
Who cannot join
- Known hematological disorders
- Known bone marrow disorders
- Known malignancy
- Chronic liver disease
- Chronic kidney disease
- Active infection at the time of assessment
Show all 9Show fewer
- Recent blood transfusion
- Current use of medications known to affect hematopoiesis
- Known immunodeficiency or systemic inflammatory disease
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
Official title: Effect of Antiseizure Medications on Complete Blood Count Parameters Among Egyptian Children With Epilepsy
This prospective study aims to assess changes in complete blood count parameters among Egyptian children with epilepsy receiving antiseizure medications.
Read the detailed description
Antiseizure medications are the mainstay of treatment for children with epilepsy. Some of these medications may affect hematological parameters including hemoglobin, white blood cell count, and platelet count.
This observational study will evaluate complete blood count parameters in newly diagnosed children with epilepsy before starting antiseizure medication and at follow-up time points after treatment initiation.
- Conditions
- Epilepsy
- Keywords
- Antiseizure medications, Complete blood count, Children, Epilepsy, Assiut
- Medical subject headings
- Epilepsy
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Children with Epilepsy on Antiseizure Medications | Newly diagnosed children with epilepsy who will receive antiseizure medications and undergo serial complete blood count assessments. |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in platelet count
Mean change in platelet count from baseline after initiation of antiseizure medication.
Measured: At 3 months
Secondary outcomes (4)
Change in hemoglobin level
Mean change in hemoglobin level from baseline after initiation of antiseizure medication.
Measured: At 3 months
Change in white blood cell count
Mean change in white blood cell count from baseline after initiation of antiseizure medication.
Measured: At 3 months
Change in absolute neutrophil count
Mean change in absolute neutrophil count from baseline after initiation of antiseizure medication.
Measured: At 3 months
Mean Platelet Count at 6 Months
Mean platelet count at 6 months after initiation of antiseizure medication..
Measured: At 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted20 Oct 2026
- Study start20 Oct 2026 (estimated)
- Primary completion20 Oct 2027 (estimated)
- Study completion1 Mar 2028 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for EpilepsyStudies of the same condition, open and under way.
- More trials run by Assiut UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 80 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Assiut University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Kholoud Ahmed Ali, Assiut University
- Investigators
- Mostafa m Embaby, prof, Study chair, Pediatrics Department, Assiut University Hospitals
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07883980
- Sponsor's protocol ID
- ASM-CBC-Assiut-2026
- Status last verified
- Oct 2026
- First submitted
- 14 Oct 2026
- Last updated
- 20 Oct 2026
- Results posted
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No